FDA abortion pill review will extend into 2027
Mifepristone report due by March as current rules remain in place

The U.S. Food and Drug Administration expects to complete its new safety study of the abortion medication mifepristone by mid-December 2026, with a final report on its findings due no later than March 2027. The timeline was disclosed in a court-ordered filing Wednesday and provides the clearest schedule yet for the review ordered by Health Secretary Robert F. Kennedy Jr.
Mifepristone was first approved by the FDA in 2000 and is used with misoprostol to end an intrauterine pregnancy through 10 weeks of gestation. The two-drug regimen is the most commonly used method of abortion in the United States. The FDA has repeatedly reviewed mifepristone and currently states that it is safe when used as directed under the agency's Risk Evaluation and Mitigation Strategy, or REMS. FDA data through December 31, 2024 had not identified new safety signals requiring changes to the drug's approved use.
The current review includes data collection, evaluation of data integrity, statistical analysis, validation and peer review. Once that work and the final report are completed, the FDA will determine whether substantive changes to the mifepristone REMS are warranted. No such decision has been made, and the review itself does not change the drug's current federal prescribing or dispensing requirements.
Under the existing REMS, mifepristone must be prescribed by a certified prescriber and can be dispensed by a certified pharmacy or under the supervision of a certified prescriber. It may currently be dispensed either in person or by mail, subject to applicable state laws.
The FDA disclosed the new timeline as part of litigation brought by Louisiana challenging federal rules allowing mifepristone to be delivered by mail. Anti-abortion organizations have pressed the Trump administration to tighten federal restrictions on the medication, while abortion-rights organizations argue that existing scientific evidence supports its continued availability. The FDA's March report, rather than the current review itself, could determine whether federal restrictions change.